Acular®
Ketorolac 0.5% · ophthalmic solution
NSAID
Approved uses
Ocular itching due to seasonal allergic conjunctivitis
One drop QID to the affected eye(s).
Inflammation following cataract surgery
One drop QID to the affected eye starting 24 hours after surgery, continuing through the first 2 weeks postoperatively.
OFF-LABELNot in the FDA label for this product
Acute pseudophakic cystoid macular edema
One drop QID, alone or combined with prednisolone acetate 1% QID, continued until the edema resolves or for 3 months, then tapered over 3 weeks.
RCT · n=28 · underpowered
Small randomized double-masked trial, 28 patients enrolled and 26 completed, CME developing 21 to 90 days after cataract extraction. A gain of 2 or more Snellen lines occurred in 6 of 9 on ketorolac alone, 8 of 9 on ketorolac plus prednisolone, and 4 of 8 on prednisolone alone; only the combination reached a mean 2-line gain, and it beat prednisolone monotherapy at every visit. Responders on ketorolac improved at a mean 1.43 months versus 2.75 months on prednisolone. Underpowered single trial, so treat as supportive rather than definitive.
Contraindications
Previously demonstrated hypersensitivity to any of the ingredients in the formulation
0.5% (5 mg/mL) solution, 5 mL fill in a 10 mL dropper bottle
Nonsteroidal anti-inflammatory drug of the pyrrolo-pyrrole group which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. Its mechanism of action is thought to be due to its ability to inhibit prostaglandin biosynthesis. In an in vitro measurement, ketorolac showed the most potent COX-1 inhibition among nepafenac, amfenac, ketorolac, and bromfenac. In a guinea pig model of ocular surface itch, the antipruritic activity of ketorolac in allergic conjunctivitis may be ascribed to preventing the biosynthesis of itch-producing PGs because ketorolac inhibited arachidonic acid-induced pruritus.
Warnings & Precautions
- Delayed healing: Topical NSAIDs may slow or delay healing, and topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
- Cross-sensitivity or hypersensitivity: Potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. Bronchospasm or exacerbation of asthma has been reported in patients with known hypersensitivity to aspirin or NSAIDs or a past medical history of asthma, so use caution in individuals who have previously exhibited sensitivities to these drugs.
- Increased bleeding time: With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or receiving other medications which may prolong bleeding time.
- Corneal effects: Topical NSAIDs may result in keratitis. In some susceptible patients, continued use may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation, which may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use and be closely monitored for corneal health.
- Corneal adverse events: Postmarketing experience suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk; use with caution in these patients. It also suggests that use more than 1 day prior to surgery or beyond 14 days post-surgery may increase the occurrence and severity of these events.
- Contact lens wear: Not to be administered while wearing contact lenses.
- Risk of contamination: Avoid allowing the tip of the bottle to contact the eye or surrounding structures, because the tip could become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Common Side Effects
The most frequent adverse reactions are transient stinging and burning on instillation, reported by up to 40% of patients in clinical trials. Other adverse reactions occurring approximately 1% to 10% of the time include allergic reactions (including eye swelling, hyperemia, and pruritus), corneal edema, iritis, ocular inflammation, ocular irritation, ocular pain, superficial keratitis, and superficial ocular infections. Corneal infiltrates, corneal ulcer, eye dryness, headaches, and blurry vision have been reported rarely. Postmarketing reports include corneal erosion, corneal perforation, corneal thinning, epithelial breakdown, and bronchospasm or exacerbation of asthma.
Pregnancy: No adequate and well-controlled studies in pregnant women; no teratogenicity seen in rats or rabbits at clinically relevant doses. Avoid in late pregnancy because prostaglandin-inhibiting drugs can close the fetal ductus arteriosus.
Lactation: Presence in human milk after topical dosing is unknown; use caution in a nursing woman.
Safety and effectiveness not established below age 2.